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Comparison of 3 Assay Systems Using a Common Probe 
Substrate, Calcein AM, for Studying P-gp Using 
a Selected Set of Compounds
PÉTER SZERÉMY,1 ÁKOS PÁL,1 DÓRA MÉHN,1 BEÁTA TÓTH,1 FERENC FÜLÖP,2 
PÉTER KRAJCSI,1 and KRISZTINA HERÉDI-SZABÓ1
The multidrug resistance protein 1 (MDR1) transporter is the most abundantly investigated adenosine triphosphate (ATP)- 
Binding Cassette (ABC) transporter protein. Multiple assay systems were developed to study MDR1-mediated transport and 
possible drug-drug interactions. Yet, as different probe substrates are used in these assays, it is difficult to directly compare 
the results. In this study, a common probe substrate was applied in 3 assay systems developed to study MDR1: the cellular 
dye efflux assay, the ATPase assay, and the vesicular transport assay. This probe substrate is calcein acetoxymethyl ester 
(calcein AM), the acetoxymethyl ester derivative of the fluorescent dye, calcein. Using a common probe allows the investiga­
tion of the effect of passive permeability on the result obtained by testing various compounds. In this study, 22 compounds 
with different logP values were tested in the above-mentioned 3 assay systems. The vesicular transport assay proved most 
sensitive, detecting 18 of 22 interactions with the protein. The ATPase assay detected 15 interactions, whereas the cellular 
dye efflux assay was the least sensitive with only 10 hits. A correlation was found between the hydrophobicity of the com­
pound and the ratio of cellular and vesicular transport IC50 values, indicating the effect o f passive permeability on the result. 
Based on hydrophobicity, the current study provides guidelines on applying the most correct tool for studying MDR1 inter­
actions. {Journal o f  Biomolecular Screening 2011:112-119)
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INTRODUCTION
Mu l t id r u g  r e s is t a n c e  p r o t e in  1 (MDR1, ABCB1, P-g p ) is a full adenosine triphosphate (ATP)-Binding Cassette (ABC) transporter comprising 2 transmembrane units 
and 2 nucleotide binding domains. Members of this protein fam­
ily use the energy from ATP hydrolysis to transport molecules 
across cell membranes.1 MDR1 was first described in the 1970s 
as a protein involved in cancer chemoresistance.2 It was soon 
revealed that MDR1 has an important role in influencing the 
ADMETox (absorption, distribution, metabolism, excretion, and 
toxicity) properties of drugs, endogenous compounds, and nutri­
ents, as this transporter is localized at all important pharmaco­
logical barriers in the body.3 MDR1 also mediates clinically
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important drug-drug interactions. For example, quinidine and 
other drugs influence the absorption and plasma concentration of 
digoxin, an important medicine with a narrow therapeutic 
index.4’5
Calcein acetoxymethyl ester (calcein AM) is a commonly 
used model substrate for MDR1.6,7 Calcein is a fluorescent dye, 
originally developed for intracellular Ca2+ ion quantification.8 
Its acetoxymethyl ester (AM) derivative is transported by 
MDR1 and was proposed to be used as a probe for transporter- 
mediated cellular chemoresistance evaluation.6 Three test sys­
tems using Calcein AM as probe substrate were evaluated in 
the current study.
The cellular dye efflux assay used in this study is a cellular 
inhibitory type assay. Calcein AM is an MDR1 transporter 
substrate with high permeability. Intracellularly, it is rapidly 
cleaved to free calcein, a low-permeability fluorescent mole­
cule that is not a substrate of the transporter protein. Therefore, 
cells expressing MDR1 accumulate only low amounts of free 
calcein, whereas increased fluorescence indicates the blockade 
of MDRl-mediated calcein AM transport. Using this simple 
system, the interaction potential of various compounds with 
MDR1 can be studied.
The ATPase assay is a membrane-based assay that works on 
the assumption that substrate transport is strictly coupled with
© 2011 Society for Laboratory Automation and Screening
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ATP hydrolysis.9 During the assay, the amount of the liberated 
inorganic phosphate is measured. A concentration-dependent 
increase in inorganic phosphate generation is an indication of 
active transport. Thus, this assay system has the potential to 
indicate substrate nature of the tested compounds. Using a 
known substrate, an activator, one can study the inhibition 
potential of compounds on the transporter. In this study, we 
used calcein AM as an activator of MDR1.
The vesicular transport assay uses inside-out membrane 
vesicles. Due to the orientation of the vesicles, the substrates 
are transported into the vesicles. In the case of low-permeabil­
ity substrates, when the compound becomes trapped in the 
vesicles and separated from the reaction buffer (e.g., rapid fil­
tration), the compound remaining in the vesicles can be quanti­
fied. Calcein AM was chosen as probe substrate in this assay 
system as well, even though the compound has high passive 
permeability.
The set of test compounds was chosen from previous publi­
cations from the lab of Polli focusing on assay systems for 
MDR1.10,11 This group has extensively studied the set in differ­
ent assay systems such as measuring MDR1-MDCKII bidirec­
tional transport, ATPase assay (activation mode), and cellular 
dye efflux assay using MDR1-MDCKII cells. A classification 
nomenclature was also generated based on the results of these 
3 assays. However, in these studies, different probe substrates 
were used for the different test systems, making data difficult 
to correlate.
Our aim was to use the same probe in the above-mentioned 
3 assay systems and correlate the results obtained with the 
hydrophobicity of the compounds. We also compared our 
results with those obtained in the work of Polli et al.10 and 
Rautio et al.11
MATERIALS AND METHODS
Materials
Calcein AM was purchased from Invitrogen (Carlsbad, CA). 
Daunorubicin, colchicine, ranitidine, methotrexate, fexofena­
dine, diphenhydramine, triamterene, digoxin, dexamethasone, 
prazosin, cyclosporine A (CsA), trimethoprim, vinblastine, 
quinidine, reserpine, erythromycin, ketoconazole, propanolol, 
verapamil, testosterone, and all other chemicals were from 
Sigma (St. Louis, MO). Amprenavir was kindly provided by 
Oliver von Richter.12 GF120918 was synthesized in house/in 
collaboration with the Institute of Pharmaceutical Chemistry at 
the University of Szeged following a published protocol.13
Membrane vesicle preparations
Sf9 cells were cultured and infected with recombinant bacu- 
lovirus coding MDR1 as described earlier.14 Purified mem­
brane vesicles from baculovirus-infected Sf9 cells were 
prepared as described previously with modifications.14
Cells of human origin overexpressing MDR1 (MDR1-K) 
were chemically selected for MDR1 overexpression. Membrane 
vesicles were purified based on a method described previously 
with modifications.15 Membrane protein content was deter­
mined using the BC A method (Pierce Biotechnology, Rockford, 
IL).
ATPase assay
The MDR1 Predeasy ATPase assay kit (Solvo Biotechnology, 
Szeged, Hungary) was used with modifications. The assay was 
performed as suggested by the manufacturer, but instead of 
using the reference activator (verapamil) in the kit, calcein AM 
(2 pM final concentration) was applied. Briefly, MDR1-Sf9 
membrane vesicles (4 pg/well) were incubated in 50 pL 
ATPase assay buffer (10 mM MgCl2, 40 mM MOPS-Tris [pH 
7.0], 50 mM KC1, 5 mM dithiothreitol, 0.1 mM EGTA, 4 mM 
sodium azide) with 5 mM ATP and various concentrations of 
test drugs for 10 min at 37 °C. ATPase activities were deter­
mined as the difference of inorganic phosphate liberation meas­
ured with and without the presence of 1.2 mM sodium 
orthovanadate (vanadate-sensitive ATPase activity).
Vesicular transport assay
In the experiments, MDRl-containing and control-inverted 
membrane vesicles (MDR1-K and K-CTRL, manufactured by 
Solvo Biotechnology) were used. The final concentration of 
calcein AM in the assay was 1 pM, unless stated otherwise in 
the figure legends. The membrane vesicles (40 pg/well) were 
incubated in 75 pL reaction buffer (50 mM MOPS-Tris, 65 mM 
KC1, 7.5 mM MgCl„ pH 7.0) in the absence or presence of 4 
mM ATP at 37 °C for 45 min, unless stated otherwise in the 
figure legends. The vesicles were separated by rapid filtration 
using a Millipore (Billerica, MA) vacuum manifold suitable for 
96-well filterplates and washed. The remaining calcein AM 
was visualized and quantified after hydrolysis of the molecule 
to free calcein in the presence of 100 pL/well 0.1 N NaOH. 
Fluorescence was measured at excitation (Ex) 485 nm, emis­
sion (Em) 520 nm using a FLUOstar Omega (BMG Labtech, 
Offenburg, Germany) fluorimeter.
Cellular dye efflux assay
K562-MDR cells were cultured as previously described,9 
and 1 x 105 cells were seeded into each well of a 96-well plate 
in Hank’s buffered salt solution (HBSS), pH 7.4. Test drugs at 
various concentrations and controls dissolved in DMSO were 
added and preincubated for 15 min at 37 °C. Calcein AM dis­
solved in HBSS containing 50 pg/mL bovine serum albumin 
(BSA) was added to a final concentration of 250 nM to each 
well (200 pL final volume), and fluorescence (Ex: 485 nm, Em: 
520 nm) was recorded every 30 s for 8 min. All wells contained 
1% DMSO. Based on the assay mechanism, the fluorescence
Journal of Biomolecular Screening 16(1); 2011 www.slas.org 113
Downloaded from jbx.sagepub.com at UNIV TORONTO on January 12. 2011
Szerémy et al.
Table 1. Physicochemical Properties and IC50 Values from Various Assay Systems
Compound logP l°gP>,4
ATPase Assay
Vesicular Transport 
Assay
Cellular Dye Efflux 
Assay
E C ,/p ld IC JpM IC Jp M ¡Cj/pM
Amprenavir 2.43 2.43 17.67 NA 20.83 43.6
Colchicine 1.46 1.46 NA NA 247.6 NA
Cyclosporine A 3.64 3.64 NA 0.21 0.21 0.49
Daunorubicin 2.32 2.32 NA 61.57 14.42 NA
Dexamethasone 1.68 1.68 155.4 NA 246.5 NA
Digoxin 2.37 1.92 40.18 NA 162.5 NA
Diphenhydramine 3.65 2.17 286.7 NA 36.2 NA
Erythromycin 2.6 1.57 24.3 NA 12.73 NA
Fexofenadine 0.85 0.95 NA NA NA NA
GF 120918 6.81 5.82 0.015 NA 0.049 0.027
Kétoconazole 4.19 4.13 0.84 NA 2.16 3.03
Methotrexate -0.54 -3.49 NA NA 88.75 NA
Prazosin 1.65 1.33 19.82 NA 5.23 30
Propranolol 2.58 0.36 NA NA 243 NA
Quinidine 2.51 0.86 8.33 NA 4.5 12.9
Ranitidine 0.98 0.22 NA NA NA NA
Reserpine 3.53 3.53 NA 5.15 0.69 1.903
Testosterone 3.37 3.37 72.73 NA 76.16 154.4
Triamterene 1.11 1.11 NA NA NA NA
Trimethoprim 1.28 1.1 NA NA NA NA
Verapamil 5.04 2.79 3.38 NA 5.15 9.45
Vinblastine 4,18 1.41 0.78 NA 0.44 26.61
NA, not applicable.
increases with increasing inhibition of MDR1-mediated efflux 
of calcein AM.
Physicochemical properties
The partition coefficient (logP) and distribution coefficient 
at pH 7.4 (logD74) of the molecules in the data set were calcu­
lated using MarvinSketch 5.3 software (ChemAxon, Budapest, 
Hungary).
Data analysis
For data analysis, GraphPad PRISM 5.0 software (GraphPad 
Software, Inc., San Diego, CA) was applied, using the follow­
ing equations: Km and Vmax values for calcein AM transport 
characterization were calculated using the Michaelis-Menten 
equation (equation (1)), after estimating the number of binding 
sites from the Hill plot:
where V is velocity (pmol substrate per mg protein per minute), 
Vmax is maximal velocity, [S] is substrate concentration in pM, 
and K is the Michaelis-Menten constant.
ill
The results of the vesicular transport, ATPase, and cellular 
dye efflux assays were analyzed using the 4-parameter logistic 
equation (equation (2)):
V - VV = v  H------SHi____EUS_,
1 +  10",,IC- K
where V is velocity (pmol substrate per mg protein per minute), 
Vmin is minimal velocity (fully inhibited transport), Vmax is maxi­
mal velocity (in the absence o f inhibitor), IC50 is inhibitor con­
centration producing 50% of maximal response, and Hill slope is 
the parameter characterizing the degree of cooperativity.
RESULTS AND DISCUSSION
Physicochemical properties o f  the compound set
The compounds were ranked based on their logP values 
calculated by the MarvinSketch 5.3 software (ChemAxon). The 
calculated values are listed in Table 1.
ATPase assay
Calcein AM, at a final concentration of 2 pM, activated the 
MDR1-containing membrane preparation to a similar extent as
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FIG. 1. Examples for compounds activating, inhibiting, or noninteracting with calcein AM-activated MDR1 transporter in the ATPase assay. 
Panel A shows an activator, verapamil (substrate), o f MDR1; panel B shows an inhibitor, GF120918, of calcein AM-activated MDR1 ATPase 
activity; panel C displays a noninteractor, ranitidine (•  activation, ■ inhibition mode).
did the reference activator, verapamil (final concentration: 40 
pM), from -15 nmol Pi/mg protein/min to -45 nmol Pi/mg 
protein/min.
Of the 22 compounds, 12 activated the MDR1 ATPase activ­
ity in the assay. Only 3 compounds acted as inhibitors of the 
MDR1 transporter activated by calcein AM, and 7 compounds 
were noninteractors. Examples for activators, inhibitors, and 
noninteractors determined in the ATPase assay are shown in 
Figure 1. The calculated EC50 and IC50 values are presented in 
Table 1.
Vesicular transport assay
Calcein AM as a probe substrate in the vesicular transport 
assay displayed Km and Vinax values of 3.50 ± 1.75 pM and 
66.43 ± 11.61 pmol/mg protein/min, respectively (Fig. 2A). 
The dynamic range of the assay was -1.5 to 2 at 1 pM concen­
tration. Control vesicles devoid of MDR1 transporter showed 
no ATP-dependent accumulation o f calcein AM (data not 
shown). The uptake into the vesicles was linear up to 45 min 
and was sensitive to osmolarity (Figs. 2B,C). Calcein AM 
quickly diffuses from the vesicles in the presence of ATP (solid 
line) and reaches an equilibrium after the reaction is stopped, 
as shown in Figure 2D.
Eighteen of the 22 compounds inhibited the MDR1-mediated 
calcein AM transport. Examples of intcractors and noninterac­
tors are shown in Figure 3. The calculated IC50 values are 
presented in Table 1.
Cellular dye efflux assay
Ten compounds inhibited the calcein AM accumulation dose 
dependently in MDR1 -expressing cells. Low-permeability 
compounds did not inhibit calcein AM transport even if they 
interacted in other assays. Examples of interactors and nonin­
teractors are shown in Figure 4. The calculated IC50 values are 
presented in Table 1.
Discussion
Utilization of the same probe substrate in different assay sys­
tems carries many advantages. Results are more comparable, and 
the strengths and limitations of the given assay systems arc more 
apparent. It should be noted that MDR1 features complex trans­
port kinetics. Depending on the probe substrate, a drug may 
potentiate or inhibit the MDR1-mediated transport due to allos­
teric interactions.16 In the current study, calcein AM was used as 
an MDR1 probe substrate in 3 assay systems: as an activator in 
the ATPase assay, as a probe substrate in the cellular dye efflux 
assay, and in the vesicular transport assay. The suitability of the 
high-passive permeability calcein AM as a probe in the vesicular 
transport assay was unexpected, as this test system typically 
works with low-permeability substrates. The mechanism is still 
unknown; hypotheses include faster inward transport than 
passive diffusion outward or partial cleavage of AM moieties 
inside the vesicles. Nevertheless, an active, ATP-dependent 
transport was observed and characterized as shown in Figure 2. 
The calcein AM accumulation is sensitive to the osmolarity of 
the buffer, as shown in Figure 2C, confirming the active nature 
of the transport.
Not all compounds interacted alike in the 3 assay systems. 
The findings are summarized in Figure 5. The compounds with 
their EAC classification (EAC: E, monolayer efflux; A, drug- 
stimulated ATPase; C, calcein AM) are ranked based on their 
partition coefficient.10 The compounds listed as noninteractors in 
the literature (NNN) were excluded from the graph as no interac­
tion was observed in any of the test systems. The only exception 
was methotrexate, which inhibited the MDR1 -mediated calcein 
AM transport in the vesicular transport assay in the current study. 
The following deviations from the literature studies were 
observed: in 3 cases (cyclosporine A, daunorubicin, GF120918) 
according to literature, no interaction was observed with the 
ATPase assay. It should be noted that the original work used only 
the activation mode of the ATPase assay and neglected the 
inhibitory approach.10 The above listed 3 compounds inhibited
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FIG. 2. Characterization of MDR1-mediated calcein AM transport in the vesicular transport assay. Panel A displays the concentration depen­
dence of the transport. The calculated Km and VmM values are 3.50 ± 1.75 pM and 66.43 ± 11.61 pmol/mg protein/min, respectively. Panel B 
shows the time dependence of the transport, whereas panel C indicates that the transport is active as it is sensitive to the osmolarity o f the buffer. 
Panel D shows the passive diffusion of calcein AM from the vesicles in the presence (solid line) or in the absence (dotted line) of adenosine 
triphosphate (ATP) after the reaction was stopped.
A B C
FIG. 3. Examples of compounds interacting and noninteracting with MDR1 in the calcein AM vesicular transport assay. Panels A (substrate of 
MDR1, verapamil) and B (inhibitor of MDR1, GF120918) show compounds that inhibit the MDR1 -mediated calcein AM transport, whereas 
panel C displays a noninteractor (ranitidine).
the calcein AM-activated MDR1 ATPase activity. In the present 
study, 2 compounds (trimethoprim and diphenhydramine) inter­
acted with MDR1 in fewer test systems compared to the litera­
ture, whereas dexamethasone interacted with the transporter in 
the ATPase assay that was not observed previously. Figure 5
demonstrates that the parameters obtained in the various assays 
systems are in good correlation.
Comparison of assay results with logP values revealed that 
the cellular dye efflux assay is limited to medium/high-perme- 
ability compounds. This may be due to the requirement of the
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FIG. 4. Examples of compounds inhibiting or noninteracting with MDR1 in the cellular dye efflux assay. Panels A (MDR1 substrate, vera­
pamil) and B (MDR1 inhibitor, GF120918) show compounds inhibiting the MDR1-mediated calcein AM efflux from the cells, whereas panel C 
shows a noninteracting molecule, ranitidine.
GF120918 (NNY) - 
verapamil (NYY) - 
kétoconazole (NYY) - 
vinblastine (YYY) 
diphenhydramine (NYY)- 
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FIG. 5. Collection of EC50/IC50 values measured in the various assay 
systems. The compounds with their EAC classification are listed 
based on their logP values (increasing from bottom to top). The NNN 
compounds are not included. Gray bars represent the IC50 values 
obtained in the cellular dye efflux assay, white bars represent the IC50 
values from the vesicular transport assay, and the black bars represent 
the EC50 or IC50 values measured in the ATPase assay.
compound to cross the lipid bilayer to be able to interact with 
the transporter. Furthermore, in agreement with our previous 
results, IC50 values shifted compared to that observed in vesic­
ular transport in the case of medium-permeability compounds.12 
In such cases, the intracellular concentration of the compounds 
might be lower than their concentration in the buffer.
The vesicular transport assay was the most sensitive, as the 
interaction with the transporter is not limited by permeability. 
This assay can be considered the best in vitro model to study 
interactions with the transporter. The ATPase assay showed 
good correlation with the vesicular transport results, although it 
had the limitation to bypass some transported substrates, such 
as cyclosporine A.
In the case of high-permeability compounds, IC50/EC50 val­
ues correlated well within the 3 assays. A tendency between 
passive permeability and IC50 shift in the cellular dye efflux 
assay could be observed. For medium-permeability com­
pounds, a shift in the cellular dye efflux assay IC50 value was 
observed, pointing to the possibility that intracellular concen­
trations of these compounds may be lower than that in the 
buffer. For low-permeability compounds, no interaction was 
observed in the cellular dye efflux assay.
Results were compared with those published by Polli et al.10 
Based on the EAC classification in von Richter et al.,12 3 of the 
22 compounds deviated (13%) from the results published. In 
the case of the ATPase assay, more interactions could be 
detected by using both the activation and inhibition modes than 
when using the activation mode alone. The inhibition mode 
ensures the detection of inhibitors and some transported sub­
strates such as GF 120918 and cyclosporine A or daunorubicin.
The ratio of cellular dye efflux assay and vesicular transport 
assay IC50 values was calculated to investigate the role of pas­
sive permeability of the compounds on the MDR1 interaction. 
Figure 6 shows a reasonable correlation between the IC50 ratios 
and the logP and logD74 values, with regression values of 0.61 
and 0.54, respectively. The only outlier was vinblastine, with 
an exceptionally high IC50 ratio of ~60. This compound was not 
included in the analysis. This finding indicates that the cellular 
IC50 value is highly influenced by the passive permeability of 
the compound. The slope of the curve in both cases was -0.71, 
indicating a close to equal contribution of hydrophobicity in the 
ratio of IC50 values.
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FIG. 6. Correlation between the ratio of cellular dye efflux assay and 
Panel A shows the correlation between the ratio of IC50 values and the 
the ratio of IC50 values and the distribution coefficient (R2 = 0.54).
B
logD74
vesicular transport IC50 values and the hydrophobicity of the compound, 
partition coefficient (R2 = 0.61). Panel B shows the correlation between
Table 2. Examples for the Suggested Use of MDR1 Assays
EAC Category MDCKII-MDR1 BA/AB“
Digoxin B-A IC50 
Value, pM b
Cellular Dye Efflux 
Assay, IC ffliM
Calcein AM MDRI VT, 
lC!(/p M
GF120918 NNY ND 0.055 0.026 0.049
Quinidine YYY 27.2 14.9 12.89 30.74
Vinblastine YYY >23 17.8 26.00 0.44
Cyclosporine A YNY 9.61 1.6 0.49 0.201
Ketoconazole NYY 1.02 3.07 3.03 2.16
Verapamil NYY 1.16 10.7 9.45 5.19
Erythromycin YYN 14.4 NA NA 36.2
Digoxin Y-N 16 NA NA 162.5
NA. no! applicable. 
■From Polli et al.10 
bfrom Rautio ct al."
Table 2 contains examples with proposed use of the various 
MDR1 assay systems. The most problematic compounds, listed 
as “nontransported substrates” in the literature such as vera­
pamil and ketoconazole, are hard to analyze in the monolayer 
assay, as the transport is saturated at low concentrations and the 
compound tends to passively cross the cell layer. Indeed, both 
verapamil and ketoconazole show an MDR 1/Mdrla-dependent 
blood-brain barrier penetration in vivo.17,18 In these cases, it is 
suggested to use other assay types—especially the ATPase 
assay, which is suitable for distinguishing substrates and inhib­
itors of MDR1.
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